Akira Shibuya

This study shows that blocking CD300a reduces renal fibrosis by improving macrophage efferocytosis and increasing neutrophil MMP9 production.

This paper identifies soluble CD155 as a systemic checkpoint that suppresses DNAM-1 signaling, leading to resistance to immune checkpoint inhibitors, and shows that an anti-sCD155 antibody can reprogram this signaling to enhance antitumor immunity.

This study identifies DNAM-1 as a key integrator of innate and adaptive immune responses in intestinal inflammation, showing it drives colitis through distinct mechanisms in ILC3s and dendritic cells and highlights its potential as a therapeutic target.